Recombinant Proteins Market Size, Share, Industry Trends and Forecast to 2030

Recombinant Proteins Market Size & CAGR in 2021

The global recombinant proteins market is expected to have a CAGR of 5.8% from 2021 to 2026. The market size is anticipated to reach USD 5040 million by the end of 2021.

COVID-19 Impact on Recombinant Proteins Market

The COVID-19 pandemic has significantly impacted the recombinant proteins market in various ways. The disruptions in the global supply chain, reduced funding for research and development, and delays in clinical trials have affected market growth. However, the increased focus on vaccine development and biologics production has created opportunities for the market.

Recombinant Proteins Dynamics

The recombinant proteins market is driven by the increasing prevalence of chronic diseases, growing demand for biopharmaceuticals, and advancements in protein engineering technologies. On the other hand, stringent regulations, high cost of production, and limited expertise in protein expression and purification are some of the challenges faced by the market.

Segments and Related Analysis

By Type

The recombinant proteins market is segmented into insulin, erythropoietin, interferon, growth hormones, and others. Insulin holds the largest market share due to the high prevalence of diabetes worldwide.

By Application

Based on the application, the market is categorized into therapeutic, research, diagnostics, and others. The therapeutic segment dominates the market, driven by the increasing demand for biologics in the treatment of various diseases.

By Region Analysis

- North America: The North American region holds the largest market share in the recombinant proteins market due to the presence of major biopharmaceutical companies and well-established healthcare infrastructure.

- Europe: Europe is the second-largest market for recombinant proteins, driven by advancements in protein engineering technologies and increasing R&D investments in biotechnology.

- Asia Pacific: The Asia Pacific region is projected to witness significant growth in the market, attributed to the increasing prevalence of chronic diseases and rising awareness about biologics.

Key Market Players and Competitive Landscape

- Amgen Inc.

- Novartis AG

- Roche Holding AG

- Biogen Inc.

- Pfizer Inc.

- Merck & Co., Inc.

Recent Happenings in the Recombinant Proteins Market

- In July 2021, Amgen Inc. announced the approval of a new recombinant protein-based therapy for the treatment of cancer.

- Novartis AG launched a new biosimilar of a popular recombinant protein drug in September 2021.

- Roche Holding AG signed a collaboration agreement with a biotech company for the development of novel recombinant proteins in October 2021.

- Biogen Inc. expanded its recombinant proteins portfolio through the acquisition of a biopharmaceutical company in November 2021.

- Pfizer Inc. received FDA approval for a new recombinant protein-based vaccine in December 2021.